ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A

Clinical trials for ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A explained in plain language.

Never miss a new study

Get alerted when new ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A trials appear

Sign up with your email to follow new studies for ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 2 Completed 1

Scientists test Two-Pronged attack on tough blood cancers

Disease control Completed

This early-stage study tested a combination of two drugs, veliparib and temozolomide, in adults with acute leukemias that had returned or were hard to treat. The main goal was to find the highest dose patients could safely tolerate. Researchers also wanted to see if the drug comb…

Matched conditions: ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Apr 01, 2026 14:43 UTC

ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A

Get alerted when new ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A trials appear

Scientists test Two-Pronged attack on tough blood cancers